@article {7740,
	title = {Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone},
	journal = {Clinical Lymphoma, Myeloma and Leukemia},
	volume = {11},
	year = {2011},
	note = {Cited By :43Export Date: 21 February 2017},
	month = {2011},
	pages = {38 - 43},
	abstract = {Background: In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time to progression and overall survival (OS) in patients with relapsed/refractory multiple myeloma compared with dexamethasone alone. In both trials the treatment was continued until disease progression or unacceptable toxicity. We conducted a subanalysis to determine if continuing therapy after achieving >= partial response (PR) improved survival. Patients and Methods: Data were collected on 212 patients who were treated with lenalidomide plus dexamethasone and achieved >= PR. Kaplan-Meier survival estimates were compared between patients on continued treatment versus patients discontinuing therapy because of adverse events, withdrawal of consent, or other reasons. Time-dependent multivariate regression analyses were used to determine the benefit of continuing treatment with lenalidomide. Results: A total of 174 patients received continued treatment until disease progression or death, and 38 patients discontinued therapy without progression. There was a trend toward longer median OS in patients who continued therapy (50.9 months vs. 35.0 months; P = .0594). When controlling for the number of previous antimyeloma therapies, β2-microglobulin levels, and Durie-Salmon stage (which adversely affected survival in these patients), continued lenalidomide treatment (HR, 0.137; 95\% CI, 0.045-0.417; P = .0005) or each additional cycle of lenalidomide (HR, 0.921; 95\% CI, 0.886-0.957; P \&lt; .0001) were both associated with longer survival. Conclusion: Continued lenalidomide treatment until disease progression after achievement of >= PR is associated with a significant survival advantage when controlling for patient characteristics. These findings should be confirmed in a prospectively designed trial. {\textcopyright} 2011 Elsevier Inc. All rights reserved.},
	keywords = {Granulocyte colony-stimulating factor, MM-009, MM-010, Neutropenia, Partial response, Thrombocytopenia},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953716823\&doi=10.3816\%2fCLML.2010.n.120\&partnerID=40\&md5=97faef542d8cd3674c3499f75fbf5566},
	author = {San-Miguel, J.F. and Dimopoulos, M.A. and Stadtmauer, E.A. and Rajkumar, S.V. and Siegel, D. and Bravo, M.-L. and Olesnyckyj, M. and Knight, R.D. and Zeldis, J.B. and Harousseau, J.-L. and Weber, D.M.}
}
